[KH explains] Why Korea has been so quick to adopt ‘global minimum tax’
Mass walkout by trainee doctors nears deadline as health services crippled
Teachers and native English instructors now required to undergo drug testing
[Today’s K-pop] Karina of aespa is dating actor Lee Jae-wook: report
Russia sending North Korea food in return for arms: Seoul defense chief
Yoon says 2,000 increase in med school quota non-negotiable
Legality issues linger as nurses fill treatment void Tuesday
Why Cha Eun-woo’s name keeps popping up in politics
University ranking hierarchy leads to wage gap later in life: study
Ultrafine dust levels this year could be severe: ministry
GC Pharma produces more COVID-19 plasma therapy amid growing demandBy Yonhap
Published : Nov. 3, 2020 - 09:12
The plasma therapy, known as GC5131, is a type of hyperimmune globulin drug that uses blood plasma taken from people who have fully recovered from COVID-19. It is considered one of the earliest treatment options.
The treatment candidate is undergoing clinical trials both at home and abroad, and it has also won emergency approval from local drug authorities for treatment purposes at three hospitals.
"The clinical trial is also expected to speed up, as patient registration at clinical trial institutions has increased as well," said a company official who asked not to be named, adding that it marks the first time for a plasma treatment to be used for treatment purposes.
The company said it is speeding up the production of its third batch and expected to provide it to medical institutions by the end of this month.
People who have recovered from COVID-19 develop natural defenses against the disease in their blood, in which antibodies are found in the part of the blood called plasma, the company said.
Key to developing potential hyperimmune globulin treatment is the collection of convalescent plasma.
A second-phase clinical trial of the investigative drug is being conducted at six local trial sites, including major general hospital Samsung Medical Center.
CoVIg-19 Plasma Alliance, a partnership of the world's leading plasma companies including GC Pharma, is also conducting a phase three clinical trial.
The global plasma collaboration was established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19. The alliance includes global blood product manufacturers, such as BPL, CSL and Takeda.
The global study has skipped both phase one and two clinical trials, GC Pharma said.
The National Institute of Allergy and Infectious Diseases under the National Institute of Health leads the global study in adult patients with COVID-19. (Yonhap)
[Herald Interview] Rival heir to Kim Ju-ae unlikely to appear: unification minister
Coupang reports first profitable year
Main opposition wrestles with exodus over nomination spat